ニュース

Targeted Oncology4 日
177Lu PSMA-617 Improves rPFS in mHSPC: PSMAddition Trial
The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...
Clinical Trials Arena on MSN5 日
Novartis reports topline outcomes from trial of Pluvicto for prostate cancer
Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.
Pharmabiz5 日
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS ...
Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive mHSPC: Basel Tuesday, June 3, 2025, 12:00 Hrs [IST] ...
Novartis’ Pluvicto Shows Promise in Early Stage Prostate Cancer
Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted ...
Novartis Says Phase III PSMAddition Trial Met Its Primary Endpoint
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...